Press releases

Thursday June 18th, 2020
Neue Forschungsinfrastruktur in Bochum: Center für systembasierte Antibiotikaforschung (CESAR) eröffnet
Download PDF
Neue Forschungsinfrastruktur in Bochum: Center für systembasierte Antibiotikaforschung (CESAR) eröffnet

Gesucht werden strukturell neue Wirkstoffe, die zur Bekämpfung
multi-resistenter Erreger eingesetzt werden können.

continue

Dortmund und Bochum, 18.Juni 2020 – Infektionskrankheiten sind in den Industriestaaten wieder die dritthäufigste Todesursache. Grund sind immer mehr Keime, die gegen vorhandene Antibiotika resistent sind. An der Ruhr-Universität Bochum (RUB) entsteht daher, in Zusammenarbeit mit der Lead Discovery Center GmbH, Dortmund (LDC), in den kommenden drei Jahren das Center für systembasierte Antibiotikaforschung (CESAR). Es soll der Erschließung neuer Wirkstoffe dienen und die Vernetzung mit Akteuren aus Wirtschaft und Hochschullandschaft regional und überregional intensivieren. Der Aufbau von CESAR wird vom Europäischen Fonds für regionale Entwicklung und dem Land NRW mit rund 4 Millionen Euro gefördert. Koordiniert wird das Center von Prof. Dr. Julia Bandow.

Mangel an strukturell neuen Substanzen
Seit Mitte des 20. Jahrhunderts wurden nur zwei neue Antibiotika-Strukturklassen entdeckt; dennoch betreiben derzeit weltweit nur wenige Unternehmen Antibiotikaforschung und -entwicklung. „Eines der Hauptprobleme ist ein akuter Mangel an vielversprechenden, strukturell neuen antibakteriellen Substanzen, die als Ausgangspunkt für Entwicklungsprojekte dienen können“, sagt Bert Klebl vom LDC.

Mit CESAR wird eine Forschungsinfrastruktur geschaffen, in der modernste Geräte für die Suche nach neuen antibakteriellen Naturstoffen und für die Analyse der Wirkung und Wirkmechanismen von Antibiotika eingesetzt werden. Auch werden Kapazitäten geschaffen, vielversprechende Substanzen in ausreichender Menge für Forschung und Entwicklung zur Verfügung zu stellen. Forscherinnen und Forscher der RUB und des LDC bringen komplementäre Expertise in Massenspektrometrie-basierten OMIC-Technologien, Assay-Entwicklung und Wirkstoffforschung zusammen, mit dem ultimativen Ziel, neue, dringend notwendige Therapiemöglichkeiten zu schaffen.

Bekannte und neue Antibiotikaproduzenten beproben
„Ausgangspunkt für die Suche nach bisher ungenutzten antibiotischen Wirkstoffen sind Bakterien, die solche Substanzen herstellen, um sich gegen konkurrierende Bakterien zu behaupten“, erklärt Julia Bandow. Die Mehrheit der heute genutzten Antibiotika wurde so in den 1940er bis 1960er Jahren entdeckt. Da die Analysemethoden seither stark verbessert wurden, hoffen die Forscher auf weitere Entdeckungen – selbst bei der Untersuchung bekannter Bakterien. Sie wollen deshalb die Gesamtheit der von diesen Bakterien ausgeschütteten Substanzen analysieren.

Die meisten Bakterien harren noch ihrer Entdeckung
Darüber hinaus will das Team aber auch andere, bisher unbekannte Bakterien und deren Stoffwechselprodukte untersuchen. „Die Mehrzahl der existierenden Bakterien ist bisher noch gar nicht beschrieben“, gibt Julia Bandow zu bedenken. „Bisher ist schätzungsweise nur ein Prozent von ihnen kultivierbar.“ Eine erste Sammlung von Mikroben im Botanischen Garten der RUB erbrachte rund 200 solcher Mikroorganismen, die bisher noch nicht untersucht wurden. Ein Bakterium kann mitunter bis zu 1.000 Substanzen ausschütten, deren Wirkung auf andere Organismen zumeist unbekannt ist. Diese Stoffe wollen die Forscherinnen und Forscher mit Hilfe von Techniken wie der Flüssigkeitschromatographie-gekoppelten Tandem-Massenspektrometrie aufspüren, um sie dann aufzureinigen und ihre Wirkung auf bakterielle Krankheitserreger zu charakterisieren.

„Was das Zentrum so einzigartig macht, ist, dass wir uns von Anfang an nicht nur auf einzelne Substanzen konzentrieren, sondern untersuchen, was eine Bakterienkultur als Ganzes produziert“, unterstreicht Julia Bandow den systembasierten Ansatz. „Auch bei der Untersuchung der Wirkung nehmen wir zunächst die gesamte Bakterienzelle in den Blick und nicht ausschließlich ein spezielles Zielprotein.“ Mit der Einrichtung des Centers für systembasierte Antibiotikaforschung wollen das LDC und die RUB dazu beitragen, die Antibiotikaresistenzkrise nachhaltig zu adressieren.

###

Kontakte

für das LDC

PR am LDC
T. +49.231.97 42 70 00
E. pr@lead-discovery.de

Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
für die Ruhr-Universität Bochum

Prof. Dr. Julia Bandow
Arbeitsgruppe Angewandte Mikrobiologie
Fakultät für Biologie und Biotechnologie
Ruhr-Universität Bochum
Tel.: +49 234 32 23102
E-Mail: julia.bandow@rub.de

###

Über das LDC
Die Lead Discovery Center GmbH wurde 2008 von der Technologietransfer-Organisation Max-Planck-Innovation gegründet, um das Potenzial exzellenter Grundlagenforschung für die Entwicklung neuer, dringend benötigter Medikamente besser zu nutzen. Das Lead Discovery Center nimmt vielversprechende Projekte aus der akademischen Forschung auf und entwickelt sie typischerweise weiter bis zu pharmazeutischen Leitstrukturen („Proof-of-Concept in Modellsystemen). In enger Zusammenarbeit mit führenden Partnern aus der akademischen Forschung und Industrie entwickelt das Lead Discovery Center ein umfangreiches Portfolio an Projekten im Bereich niedermolekularer Wirkstoffe sowie therapeutische Antikörper mit außergewöhnlich hohem medizinischem und kommerziellem Potenzial.

Das Lead Discovery Center ist der Max-Planck-Gesellschaft langfristig verbunden und arbeitet mit Partnern wie AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson Innovation, Merck KGaA, Qurient, Roche, Sotio, verschiedenen Investoren sowie mit führenden Zentren für Wirkstoffforschung weltweit zusammen.

Tuesday June 16th, 2020
LDC and Qurient Launch Start-up QLi5 Therapeutics in Dortmund, Germany
Download PDF
LDC and Qurient Launch Start-up QLi5 Therapeutics in Dortmund, Germany

Dortmund, Germany, June 16th, 2020 — The Lead Discovery Center GmbH (LDC) and the South Korean drug development specialist Qurient have founded QLi5 Therapeutics GmbH, together with their partners, the Max Planck Society (MPG) and Nobel laureate Prof. Huber, emeritus director of the Max Planck Institute for Biochemistry. Dortmund based QLi5 Therapeutics licensed novel proteasome inhibitors from LDC and its partners. QLi5 Therapeutics will advance these towards preclinical and clinical development for the treatment of cancers as well as inflammatory and autoimmune disorders.

continue

The novel proteasome inhibitors were generated within a long standing and successful collaboration between the LDC and Prof. Huber. Combining Prof. Huber’s vast expertise in the field of proteasome with the LDC’s drug discovery capabilities, the partners have created a portfolio of proteasome inhibitors with unique binding characteristics and favourable pharmacodynamic properties. The further development in the joint venture with Qurient is the outcome of a successful strategic partnership between Qurient, LDC and Max Planck.

“The proteasome is a real treasure chest,” Prof. Huber comments, “and the launch of Qli5 Therapeutics enables us to harness its potential for the treatment of many diseases. Our new generation of proteasome inhibitors is set to overcome key challenges that have so far hampered a broader application of the first generation of covalently acting proteasome inhibitors.” The proteasome plays an important role in cell regulation by degrading proteins and represents a well established clinical target for the treatment of liquid tumours, in particular multiple myeloma.

“We believe the LDC’s innovative proteasome inhibitors hold exceptional potential, and we are excited to be part of QLi5 Therapeutics to jointly advance them towards preclinical and clinical testing,” Kiyean Nam, CEO and CSO of Qurient adds. “We very much appreciate the LDC as long-term partner and prime source of external innovation.” Over the last years, Qurient has licensed two other inhibitor projects from the LDC, targeting the kinases, Axl and CDK7 respectively. Both leads have made considerable progress since, e.g. nomination for clinical development.

“The foundation of Qli5 Therapeutics is the current peak of our trustful and long-term collaborations with Prof. Huber and Qurient, our exceptionally strong and committed South Korean partner,” Bert Klebl, CEO and CSO of the LDC comments. “This joint venture is a wonderful step forward in our mutual relationship and it is a great opportunity to translate the potential of the proteasome complex into more tangible benefits for patients.”

“Having previously licensed assets to Qurient, we are delighted to now jointly start-up a venture with Qurient. QLi5 provides excellent prospects to enable a much needed next generation of proteasome inhibitors. Bringing the company on track together with Qurient has been a swift and smooth endeavour”, adds Dieter Link, Licensing Manager at Max Planck Innovation GmbH.

# # #

>> Contact
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #

About Qurient
Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient mainly focuses on development of novel therapeutics from discovery to human proof of concept stages through virtual R&D project management platform. Qurient currently has three programs in clinical development: Q301, a topical leukotriene inhibitor for atopic dermatitis, completed Phase 2b study; telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for tuberculosis, completed Phase 2 study; and Q702, entering Phase 1/2 study under US FDA. Qurient recently nominated Q901, a selective CDK7 inhibitor, as a preclinical candidate for solid tumors, which is expected to enter the clinic in 2021.
Further information: www.qurient.com

About LDC
The Lead Discovery Center was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential.
The Lead Discovery Center sustains a long-term partnership with the Max Planck Society and KHAN-I technology transfer GmbH & Co.KG. LDC has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient and Sotio as well as leading translational drug discovery centers. More recently, LDC and KHAN-I are transferring their assets also into spin-outs for syndication with other investors.
Further information: www.lead-discovery.de

About Max Planck Innovation
Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary, team MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress.
Further information: www.max-planck-innovation.com

Tuesday June 16th, 2020
LDC und Qurient bringen Start-up QLi5 Therapeutics in Dortmund auf den Weg
Download PDF
LDC und Qurient bringen Start-up QLi5 Therapeutics in Dortmund auf den Weg

Dortmund, 16. Juni 2020 – Die Lead Discovery Center GmbH (LDC) und der südkoreanische Arzneimittel-Entwickler Qurient haben in enger Kooperation mit weiteren Partnern die QLi5 Therapeutics GmbH gegründet. Die Partner sind die Max-Planck-Gesellschaft (MPG) und der Nobelpreisträger Prof. Huber, emeritierter Direktor des Max-Planck-Instituts für Biochemie. Die in Dortmund ansässige QLi5 Therapeutics hat neue Proteasom-Inhibitoren vom LDC und seinen Partnern lizenziert, um sie in die präklinische und klinische Prüfung voranzubringen und für die Behandlung von Krebs-, Entzündungs- und Autoimmunerkrankungen zu entwickeln.

continue

Die Proteasom-Inhibitoren wurden im Rahmen einer langfristigen erfolgreichen Kooperation von LDC und Prof. Huber entwickelt, wobei Prof. Huber seine führende Expertise auf dem Gebiet des Proteasoms eingebracht hat und das LDC seine besondere Kompetenz im Bereich Wirkstoffentwicklung. Gemeinsam haben sie ein Portfolio an Proteasom-Inhibitoren mit einzigartigen Bindungseigenschaften und günstigen pharmakodynamischen Eigenschaften etabliert. Durch die erfolgreiche, strategische Zusammenarbeit von LDC, Qurient und MPG ist es dann gelungen, ein Joint Venture mit Qurient zur Weiterentwicklung dieses Ansatzes aufzubauen.

„Das Proteasom ist eine wahre Schatztruhe”, so Prof. Huber, „und der Start von QLi5 Therapeutics erlaubt es uns, sein Potenzial zur Behandlung vielfältiger Krankheiten auszuschöpfen. Unsere neuen Proteasom-Inhibitoren haben beste Aussichten, die Schwierigkeiten der ersten Generation kovalent bindender Proteasom-Inhibitoren zu überwinden, die eine breitere Anwendung des Ansatzes bislang behindert haben.” Das Proteasom spielt eine wichtige Rolle in der Zellregulation, indem es Proteine abbaut. Als Zielstruktur zur Behandlung flüssiger Tumore ist es klinisch gut etabliert, insbesondere beim Multiplen Myelom.

„Wir sind vom Potenzial der innovativen Proteasom-Inhibitoren aus dem LDC überzeugt und freuen uns, diese im Team mit QLi5 in die präklinische und klinische Prüfung voranzubringen“, ergänzt Kiyean Nam, CEO und CSO von Qurient. „Wir schätzen das LDC als langfristigen Partner und wichtige Quelle von Innovation.“ Im Laufe der vergangenen Jahre hat Qurient zwei weitere Projekte vom LDC lizenziert, welche auf die Entwicklung von Kinaseinhibitoren abzielen. Beide Projekte haben seitdem deutliche Fortschritte gemacht, z.B. bis hin zu einer Nominierung für die klinische Entwicklung.

„Die Gründung von Qli5 Therapeutics ist der Höhepunkt einer vertrauensvollen, langfristigen Kooperation mit Prof. Huber und Qurient, unserem außergewöhnlich leistungsfähigen und engagierten Partner in Südkorea”, meint Bert Klebl, Geschäftsführer und wissenschaftlicher Direktor des LDC. „Dieses Joint Venture ist ein großartiger Schritt vorwärts in unserer Beziehung und eine wertvolle Chance, das Potenzial des Proteasoms in praktischen Nutzen für Patienten zu übertragen.“

„Nachdem wir bereits Projekte an Qurient lizenziert haben, freuen wir uns jetzt sehr, gemeinsam ein Unternehmen auf den Weg zu bringen. QLi5 hat beste Chancen, die dringend benötigte nächste Generation an Proteasom-Inhibitoren zu realisieren. Die gemeinsame Gründung von Qurient lief sehr zügig und konstruktiv“, so Dieter Link, Lizenzmanager bei Max-Planck-Innovation.

# # #

>> Kontakt
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #

Über Lead Discovery Center GmbH
Die Lead Discovery Center GmbH wurde 2008 von der Technologietransfer-Organisation Max-Planck-Innovation gegründet, um das Potenzial exzellenter Grundlagenforschung für die Entwicklung neuer, dringend benötigter Medikamente besser zu nutzen. Das Lead Discovery Center nimmt vielversprechende Projekte aus der akademischen Forschung auf und entwickelt sie typischerweise weiter bis zu pharmazeutischen Leitstrukturen („Proof-of-Concept“) in Modellsystemen. In enger Zusammenarbeit mit führenden Partnern aus der akademischen Forschung und der Industrie entwickelt das Lead Discovery Center ein umfangreiches Portfolio an Projekten im Bereich niedermolekularer Wirkstoffe sowie therapeutische Antikörper mit außergewöhnlich hohem medizinischem und kommerziellem Potenzial. Das Lead Discovery Center ist der Max-Planck-Gesellschaft langfristig verbunden und arbeitet mit Partnern wie AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson Innovation, Merck KGaA, Qurient, Roche, Sotio, verschiedenen Investoren sowie mit führenden Zentren für Wirkstoffforschung weltweit zusammen.
Weitere Informationen: www.lead-discovery.de

 
Über Max-Planck-Innovation
Als Technologietransfer-Organisation der Max-Planck-Gesellschaft ist Max-Planck-Innovation das Bindeglied zwischen Industrie und Grundlagenforschung. Mit unserem interdisziplinären Team beraten und unterstützen wir die Wissenschaftlerinnen und Wissenschaftler der Max-Planck-Institute bei der Bewertung von Erfindungen, der Anmeldung von Patenten sowie der Gründung von Unternehmen. Der Industrie bieten wir einen zentralen Zugang zu den Innovationen der Max-Planck-Institute. Damit erfüllen wir eine wichtige Aufgabe: Den Transfer von Ergebnissen der Grundlagenforschung in wirtschaftlich und gesellschaftlich nützliche Produkte.
Weitere Informationen: www.max-planck-innovation.de

Über Qurient
Qurient ist ein biopharmazeutisches Unternehmen, das an der koreanischen Börse notiert ist (KRX 115180). Mit Hilfe einer virtuellen R&D Projektmanagement-Plattform entwickelt Qurient neue Therapeutika von der Entdeckung bis zum Proof-of-Concept beim Menschen. Qurient hat aktuell drei Programme in der klinischen Entwicklung: Q301, ein topischer Leukotrien-Inhibitor zur Behandlung atopischer Dermatitis (Phase 2b abgeschlossen); Telacebec (Q203), ein innovativer, oral verfügbarer Cytochrom-bc1-Inhibitor zur Behandlung von Tuberkulose (Phase 2 abgeschlossen); und Q702 (zur Phase 1/2 zugelassen durch die FDA). Qurient hat kürzlich Q901, einen selektiven CDK7-Inhibitor, als präklinischen Kandidaten für solide Tumore nominiert. Start der klinischen Prüfungen ist voraussichtlich 2021.
Weitere Informationen: www.qurient.com

Tuesday May 26th, 2020
Qurient Announces U.S. FDA Clearance of IND Application for Q702, a Novel Cancer Immunotherapy
Download PDF
Qurient Announces U.S. FDA Clearance of IND Application for Q702, a Novel Cancer Immunotherapy

Phase 1 clinical study in patients with advanced solid tumor expected to start in 3Q20

continue

Seongnam-si, Korea, and Dortmund, Germany, May 26, 2020 — Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company in Korea, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q702, orally available immuno-oncology therapeutic small molecule targeting Axl, Mer and CSF1 receptor tyrosine kinases.
 
Under this IND, Qurient plans to initiate a Phase 1 clinical study in patients with advanced solid tumors for whom standard of care therapies are currently ineffective. The Phase 1 study is expected to begin in 3Q2020 and is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Q702. The study will be conducted at multiple clinical centers in the United States.
 
“IND clearance for Q702 is an important milestone presenting a novel drug candidate that not only boosts immune cells in the tumor microenvironment but also makes tumor cells more visible to the immune system,” said Kiyean Nam, Ph.D., CEO of Qurient. “We believe Q702 may have an important role in the cancer immunotherapy, improving clinical responses in patients who are unresponsive and/or refractory to currently available immunotherapy.”
 
Q702 is an orally available, selective Axl/Mer/CSF1R triple kinase inhibitor showing significant in vivo activity as monotherapy as well as in combination with anti-PD-1 antibody. Q702 not only modulates innate immune components such as myeloid derived suppressor cell (MDSC), tumor associated macrophage (TAM) in tumor micro-environment (TME), but also increases MHC I expression in tumor cell.
 
The Axl inhibitor program was licensed from Lead Discovery Center (LDC) and the Max Planck Society at lead stage and further optimized by Qurient. The research program initially originated from Professor Axel Ullrich’s laboratory from the Max Planck Institute of Biochemistry, Martinsried/Germany.
 
“We are excited to see the progress in this project and are looking forward to the application in humans in the near future. With Qurient, we have identified an ideal partner for this project and we are more than happy about the results of our strategic partnership with them,” said Matthias Stein-Gerlach, Senior Patent and Licensing Manager at Max Planck Innovation GmbH.
 
”Reaching a clinical candidate for development is one of the most important milestones in our partnerships,” adds Bert Klebl, CEO and CSO of the LDC. “Starting an early-stage collaboration with Ullrich’s lab from Max Planck, leading to a licensing agreement with Qurient, we jointly mastered the pharmaceutical research phase and are now very eager to receive the results from this drug candidate in patients. Starting with this program, we have since built a sustainable and strong partnership with our partner Qurient, focusing on the translation of innovative biology and drug discovery programs from LDC’s academic network.”

# # #

>> Contact
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #

About Qurient
 Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient mainly focuses on development of novel therapeutics from discovery to human proof of concept stages through virtual R&D project management platform. Qurient currently has three programs in clinical development: Q301, a topical leukotriene inhibitor for atopic dermatitis, completed Phase 2b study; telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for tuberculosis, completed Phase 2 study; and Q702, entering Phase 1/2 study. Qurient recently nominated Q901, a selective CDK7 inhibitor, as a preclinical candidate for solid tumors, which is expected to enter the clinic in 2021. For more info, please visit www.qurient.com.
 
About LDC
Lead Discovery Center GmbH was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential. The Lead Discovery Center sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co.KG and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient,  and Sotio, e.g.In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation. Further information at: www.lead-discovery.de.
 
About Max Planck Innovation
Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary team, MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress. Further information at: www.max-planck-innovation.com.

Wednesday May 13th, 2020
Corona: Impfung ohne Nadel
Download PDF
Corona: Impfung ohne Nadel

Wissenschaftler entwickeln ein Verfahren, mit dem ein Impfstoff über die Haut aufgenommen werden kann

continue

Potsdam und Dortmund, 13. Mai 2020 — Das Max-Planck-Institut für Kolloid- und Grenzflächenforschung in Potsdam und der Technologietransfer-Fond KHAN-I entwickeln gemeinsam mit dem Lead Discovery Center in Dortmund ein Impfverfahren gegen SARS-CoV2. Die Forscherinnen und Forscher hoffen, in den kommenden Jahren über den gezielten Impfstofftransport über die Haut Immunität und Schutz gegen das Virus aufbauen zu können.

SARS-CoV2 hat mittlerweile über 3,6 Millionen Menschen weltweit infiziert und ist verantwortlich für über 250.000 Todesfälle. Die Dunkelziffer wird deutlich höher eingeschätzt. Für Milliarden Menschen bestimmt diese Pandemie gegenwärtig den Lebensalltag und auch langfristig sind die Auswirkungen auf Weltwirtschaft und Gesundheitssysteme schwerwiegend. In Industrie und akademischer Forschung wird über viele Lösungsansätze an der schnellen Entwicklung eines wirksamen, anhaltenden Impfschutzes gearbeitet, der in der Zukunft die Notwendigkeit drastischer Maßnahmen zur Ausbreitungsbeschränkung solcher Erkrankungen vermeiden kann.
 
Impfstoffe stellen die einzige langfristige Möglichkeit dar, einen Erreger zu bekämpfen. Im Zusammenhang mit SARS-CoV2 werden vor allem neuartige und schnell auf neue Viren anpassbare Impftechnologien forciert, die auf die Applikation von Nukleinsäure-Wirkstoffen oder Verwendung von Adenovirus-Vektoren beruhen. Fast alle dieser Technologien beruhen auf der Injektion des Impfstoffs in den Muskel des Patienten.
 
Gezielte Aktivierung der Langerhans Zellen
In der Haut ist die Dichte der Immunzellen allerdings höher als in Muskeln: Hier befinden sich auch die sogenannten Langerhans-Zellen. Diese Zellen aktivieren und koordinieren die anti-virale Antwort im Körper [1].

Die Arbeitsgruppe von Christoph Rademacher am Max-Planck-Institut für Kolloid- und Grenzflächenforschung hat eine neue Plattformtechnologie entwickelt, mit dem diese Langerhans-Zellen gezielt angesprochen werden können, das Langerhans Cell Targeted Delivery System (LC-TDS) [2, 3]. Dieses System soll es ermöglichen, Impfstoffe direkt auf die Haut aufzutragen oder mit Mikronadeln zu injizieren. Dafür nutzt es die natürlichen Mechanismen des Immunsystems. „Wir gehen davon aus, dass unser System alle Impfstoffe freisetzen kann, die Proteine, Peptide oder mRNA verwenden“, sagt Christoph Rademacher, Gruppenleiter am Potsdamer Max-Planck-Institut und Haupterfinder der neuen Technologie.
 
Neue Plattformtechnologie ermöglicht effiziente Freisetzung des Impfstoffs
Die zentrale Rolle spielt beim LC-TDS ein hoch-spezifischer chemischer Baustein, der das Andocken ausschließlich an Langerhans Zellen ermöglicht und dort eine effiziente Freisetzung des Impfstoffs erlaubt. Mit der Anpassung der bestehenden LC-TDS-Technologie auf SARS-CoV2 versuchen die Forscherinnen und Forscher des Max-Planck-Institut für Kolloid- und Grenzflächenforschung mithilfe der schnell mobilisierten Finanzierung von KHAN-I in Zusammenarbeit mit dem Lead Discovery Center in Dortmund nun ein schnell verfügbares Impfverfahren zu entwickeln. „Die Finanzierung durch KHAN-I ist der erste Schritt für die LC-TDS Technologie in die unternehmerische Selbstständigkeit als künftige Cutanos GmbH, der wir mit großer Hoffnung auf eine breite Anwendbarkeit entgegensehen“, sagt Bert Klebl, Geschäftsführer von KHAN-I und ergänzt: „Weitere Investoren sind willkommen“.
 
“Durch die vom KHAN-I Fund finanzierte Zusammenarbeit zwischen Lead Discovery Center und Max-Planck-Institut wurden äußerst kompetente Partner zusammengebracht und ein sehr guter Weg gefunden, die vielversprechende LC-TDS Technologie schnell für die Entwicklung eines SARS-CoV2-Impfstoffs zur Verfügung stellen zu können”, fügt Mareike Göritz, Patent- und Lizenzmanagerin beim Lizenzgeber und Vertragspartner Max-Planck-Innovation hinzu.
 
 

# # #

>> Kontakt
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #
 
Über Max-Planck-Institut für Kolloid- und Grenzflächenforschung
Im Mittelpunkt steht die Erforschung und Kontrolle von sehr kleinen bzw. sehr dünnen Strukturen im Nano- und Mikrometerbereich. Diese winzigen Strukturen bestimmen die Eigenschaften von Materialien und Bio-Systemen. Ein tieferes Verständnis ist Schlüssel für zahlreiche Innovationen wie z.B. neuartige Impfstoffe, intelligente Wirkstoffträger sowie adaptive Biomaterialien. Auch an der Energiegewinnung der Zukunft und der Vermeidung von CO2-Emissionen wird hier geforscht.
 
Über KHAN-I
KHAN-I ist ein Technologietransfer-Fond, der Ende 2019 ins Leben gerufen wurde, u.a. mit Mitteln des Europäischen Investitionsfonds, der Max-Planck-Förderstiftung und der Austria Wirtschaftsservice GmbH. Er investiert in Projekte und Start-up Firmen, die innovative Therapien entwickeln.

Über Lead Discovery Center
Die Lead Discovery Center GmbH wurde 2008 von der Technologietransfer-Organisation Max-Planck-Innovation gegründet, um das Potenzial exzellenter Grundlagenforschung für die Entwicklung neuer, dringend benötigter Medikamente besser zu nutzen. Das Lead Discovery Center nimmt vielversprechende Projekte aus der akademischen Forschung auf und entwickelt sie typischerweise weiter bis zu pharmazeutischen Leitstrukturen („Proof-of-Concept“ in Modellsystemen). In enger Zusammenarbeit mit führenden Partnern aus der akademischen Forschung und Industrie entwickelt das Lead Discovery Center ein umfangreiches Portfolio an Projekten im Bereich niedermolekularer Wirkstoffe sowie therapeutische Antikörper mit außergewöhnlich hohem medizinischem und kommerziellem Potenzial. Weitere Informationen: www.lead-discovery.de
 
Über Max-Planck-Innovation
Als Technologietransfer-Organisation der Max-Planck-Gesellschaft ist Max-Planck-Innovation das Bindeglied zwischen Industrie und Grundlagenforschung. Mit unserem interdisziplinären Team beraten und unterstützen wir die Wissenschaftlerinnen und Wissenschaftler der Max-Planck-Institute bei der Bewertung von Erfindungen, der Anmeldung von Patenten sowie der Gründung von Unternehmen. Der Industrie bieten wir einen zentralen Zugang zu den Innovationen der Max-Planck-Institute. Damit erfüllen wir eine wichtige Aufgabe: Den Transfer von Ergebnissen der Grundlagenforschung in wirtschaftlich und gesellschaftlich nützliche Produkte. Weitere Informationen: www.max-planck-innovation.de
 

 
1.         Wong, E., et al., Langerhans Cells Orchestrate the Protective Antiviral Innate Immune
            Response in the Lymph Node. Cell Rep, 2019. 29(10): p. 3047-3059 e3.
2.         Wamhoff, E.C., et al., A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell
            Targeting. ACS Cent Sci, 2019. 5(5): p. 808-820.
3.         Schulze, J., et al., A Liposomal Platform for Delivery of a Protein Antigen to
            Langerin-Expressing Cells.
Biochemistry, 2019. 58(21): p. 2576-2580.

Wednesday May 13th, 2020
Corona: Vaccination Without Needle?
Download PDF
Corona: Vaccination Without Needle?

Scientists are developing a procedure whereby vaccines can be absorbed through the skin.

continue

Potsdam and Dortmund, Germany, May 13, 2020 — The Max Planck Institute of Colloids and Interfaces in Potsdam and the Technology Transfer Fund KHAN-I are developing a vaccine procedure for SARS-CoV2 together with the Lead Discovery Center in Dortmund. The researchers hope that within the next few years, they will be able to establish immunity to and protection from the virus using targeted vaccine transport via the skin.

SARS-CoV2 has already infected more than 3.6 million people worldwide, and is responsible for over 250.000 deaths. The number of unreported cases is estimated to be significantly higher. The pandemic is affecting the everyday life of billions of people, with long-term severe consequences for the global economy and health systems. Industry and academia are currently applying many different approaches to the rapid development of effective, sustained immunization in order to avoid the drastic measures required to prevent the spread of such diseases.
 
Vaccines are the only possibility for defeating an infectious agent in the long term. In the case of SARS-CoV2, novel vaccine technologies that can quickly be adapted to new viruses are being pushed, particularly those based on the application of nucleic acids or the use of adenovirus vectors. Nearly all these technologies involve the injection of the vaccine into the patient’s muscle.
 
Targeted activation of Langerhans cells
The concentration of immune cells is, however, higher in the skin than in muscle. So-called Langerhans cells are also present in the skin, and these activate and coordinate the body’s antiviral response [1].
 
Christoph Rademacher’s research group at the Max Planck Institute of Colloids and Interfaces has developed a new platform technology that specifically addresses Langerhans cells: the Langerhans Cell Targeted Delivery System (LC-TDS) [2, 3]. This system enables vaccines to be applied directly onto the skin or injected with microneedles, thereby using the immune system’s natural mechanisms. “We expect our system to be able to release all vaccines that use proteins, peptides or mRNA,” says Christoph Rademacher, Group Leader at the Max Planck Institute of Colloids and Interfaces and main inventor of the new technology.
 
New platform technology allows efficient vaccine release
The central role in the LC-TDS is played by a highly specific chemical component that enables exclusive binding to Langerhans cells, where the efficient release of vaccine can then take place. By adapting existing LC-TDS technology to SARS-CoV2, researchers at the Max Planck Institute of Colloids and Interfaces – with the help of the swiftly mobilized KHAN-I financing – now aim to develop a rapidly available vaccination procedure in cooperation with the LDC in Dortmund. “The KHAN-I financing marks the first step for LC-TDS technology on the road to future entrepreneurial independence as Cutanos GmbH, which we look forward to with high hopes for wide-ranging applications,” says Bert Klebl, CEO of KHAN-I, adding: “Further investors are welcome.”
 
“With the KHAN-I-funded collaboration between the LDC and the Max Planck Institute, extraordinarily competent partners have been brought together, and an excellent way has been found to quickly make this promising LC-TDS technology available for the development of a SARS-CoV2 vaccine,” adds Mareike Göritz, Patent & License Manager at the licensor and contractual partner Max Planck Innovation.
 
 
# # #

 

>> Contact
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #

 
About the Max Planck Institute of Colloids and Interfaces
The institute focuses on the exploration and control of very small and very thin structures in in the nanometer and micrometer ranges. These minute structures determine the properties of materials and biosystems. A deeper understanding is the key to numerous inventions, e.g. new vaccines, smart drug carriers and adaptive biomaterials. Future energy production and avoidance of CO2 emissions are further areas of research.
 
About KHAN-I
KHAN-I is a technology transfer fund founded at the end of 2019 and financed, among others, by the European Investment Fund, the Max Planck Foundation and the Austria Wirtschaftsservice GmbH. It invests in projects and start-ups developing innovative therapies.
 
About the Lead Discovery Center
The Lead Discovery Center was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential. Further information: www.lead-discovery.de
 
About Max Planck Innovation
Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary, team MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress.
 
 
1.         Wong, E., et al., Langerhans Cells Orchestrate the Protective Antiviral Innate Immune
            Response in the Lymph Node.
            Cell Rep, 2019. 29(10): p.3047-3059 e3.
2.         Wamhoff, E.C., et al., A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell
            Targeting. ACS Cent Sci, 2019. 5(5): p. 808-820.
3.         Schulze, J., et al., A Liposomal Platform for Delivery of a Protein Antigen to
            Langerin-Expressing Cells.
Biochemistry, 2019. 58(21): p. 2576-2580.
 

Friday March 27th, 2020
Das LDC überbrückt das Tal des Todes
Download PDF
Das LDC überbrückt das Tal des Todes

Das 2008 gegründete Lead Discovery Center (LDC) schließt die Finanzierungslücke zwischen Grundlagenforschung und Medikamentenentwicklung.
Im Gespräch beschreibt Geschäftsführer Bert Klebl die enge Zusammenarbeit mit Wissenschaftlern und den Vorbildcharakter des LDC.

Thursday February 27th, 2020
LDC-associated company Quench Bio Closes USD 50M Series A Financing to Advance First-in-Class Medicines against Severe Inflammatory Diseases
Download PDF
LDC-associated company Quench Bio Closes USD 50M Series A Financing to Advance First-in-Class Medicines against Severe Inflammatory Diseases

Dortmund and Munich, Germany, February 27, 2020 — The Lead Discovery Center GmbH (LDC), the Max Planck Society (MPG) and Max Planck Innovation (MI) announce that their associated company Quench Bio Inc., Cambridge, USA has raised USD 50 million in a Series A financing round. The financing was led by RA Capital Management (RA Capital) and included Abbvie Ventures as well as co-founders and seed investors Atlas Venture (Atlas) and Arix Bioscience plc (Arix).

continue

Quench Bio develops therapies targeting innate immune pathways to treat autoimmune and inflammatory diseases. The approach centres on a pore-forming protein called Gasdermin D that was identified as a potential new target during a collaboration between the Max Planck Institute for Infection Biology in Berlin, Germany, the Max Planck Institute for Molecular Physiology in Dortmund, Germany and the LDC.

In close collaboration, the partners generated a series of Gasdermin inhibitors that prevent the release of inflammatory cytokines, alarmins and neutrophil extracellular traps (NETs), thereby validating the protein as a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis. The specific targeting of Gasdermin represents a novel mode of action for the treatment of numerous inflammatory diseases associated with NETosis, including rheumatoid arthritis, lupus, multiple sclerosis and nonalcoholic steatohepatitis (NASH). When Quench Bio was founded in 2018, it received an exclusive license to IP relating to the therapeutic use of Gasdermin by LDC and MI. The co-founders, besides LDC and MI, include Atlas, Arix and MPG Directors Prof. Arturo Zychlinsky and Prof. Herbert Waldmann, among others.

The company has brought together an experienced team of drug developers and scientists, led by Chief Executive Officer Samantha Truex, the former Chief Business Officer of Padlock Therapeutics, which was acquired by Bristol Myers Squibb in 2016.

“With such a strong team of entrepreneurs, scientists and investors, the company is in an excellent position to deliver on the promise of an exciting new therapeutic platform concept,” says Bert Klebl, one of the LDC’s managing directors. “The emergence of Quench exemplifies the power of our collaborative approach to drug discovery. Together, we have been able to translate the discovery of Gasdermin and its role in inflammatory cell death into a validated therapeutic strategy with game-changing potential in many inflammation-related indications.”

“The LDC has already demonstrated a track record of successful outlicensing deals to pharma companies. The foundation of Quench Bio represents a major step in the spin-off sector. This VC-backed form of commercialization of MPG/LDC projects allows exquisitely well-focused, comprehensive and fast development,” adds Dieter Link, licensing manager at Max Planck Innovation.

 “I’m delighted by the strong support from MPG, MI, LDC and our investors, which enables us to advance our scientific findings towards medical practice,” adds Prof. Arturo Zychlinsky, Director of the Max Planck Institute for Infection Biology. “Targeting inflammatory cell death pathways is a unique approach and may provide new opportunities for patients who currently have very limited treatment options.”

“Gasdermins are among, if not the most innovative and truly novel targets for the treatment of inflammatory diseases. They offer multiple opportunities for a whole flight of drug discovery programs,” adds Prof. Herbert Waldmann, Director at the Max Planck Institute of Molecular Physiology and Member of the Board of Directors of Quench Bio. “The Quench team is highly experienced in drug discovery and commands in-depth knowledge in the relevant disease areas, so that the company is ideally positioned for success.”

# # #

 

About Quench Bio

Quench Bio is a biotechnology company leveraging new insights into Gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases. Quench’s lead compounds target and inhibit the pore-forming protein Gasdermin D, a central player in both pyroptosis and NETosis pathways that mediates the release of inflammatory cytokines, alarmins, DNA and NETs. Quench Bio launched in January 2020 with USD 50 million from leading life science investors including Atlas Venture, Arix Bioscience, RA Capital and AbbVie Ventures.

To learn more, please visit www.quenchbio.com.

 

About LDC

The Lead Discovery Center was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential.

The Lead Discovery Center sustains a long-term partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Johnson & Johnson Innovation, Roche and Sotio as well as various investors leading translational drug discovery centers around the globe.

Further information at: www.lead-discovery.de

 

About Max Planck Innovation

Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary, team MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress.

Further information at: www.max-planck-innovation.com

Wednesday February 5th, 2020
German–Chinese consortium to develop new drugs for the treatment of heart failure and cardiac hypertrophy
Download PDF
German–Chinese consortium to develop new drugs for the treatment of heart failure and cardiac hypertrophy

February, 5th  2020, Dortmund – The development of a new drug for the treatment of heart failure and cardiac hypertrophy is a primary goal of “ChInValue – NRW–China Cooperations: GRK5 Inhibitors”. The project is being coordinated by the Lead Discovery Center (LDC) and conducted in cooperation with the Leibniz Institute for Analytical Sciences (ISAS) and two Chinese partners: Shanghai Jemincare Pharmaceutical Co. and Makohs Biotech. The German–Chinese consortium will devote itself to the fight against cardiac insufficiency and hypertrophy until the end of 2022. The German partners are being funded by a grant of around EUR 1 million from the German Federal Ministry of Education and Research (BMBF).

continue

Research will focus on GRK5, a protein kinase that has so far received little attention in drug development, despite being implicated in the development of heart failure or hypertrophic heart muscle in the vast majority of cases. The aim of the project is to develop low-molecular-weight substances that inhibit the pathological processes mediated by GRK5.

“Our ambitious goal is to develop a drug candidate that is ready to enter preclinical development by the end of this three-year project,” says LDC’s Managing Director and CSO, Dr Bert Klebl.

“We hope to develop an effective new therapy from which heart disease patients can profit in the near future,” explains the ISAS scientific director and head of the Biomedical Research Department, Prof. Kristina Lorenz, a pharmacologist specializing in the treatment of cardiovascular diseases.  

Financial support is being provided by the German Federal Ministry of Education and Research as part of its funding programme “InterSPIN – internationalization of leading-edge clusters, forward-looking projects and comparable networks”. Within this context, BIO.NRW and BIO Clustermanagement NRW GmbH have conceived and realized the internationalization alliance „NRW-China Cooperations: A strategic perspective for innovative life science SME value chains”, of which this project in the fight against heart failure is a part.

###

The author is responsible for the content of this publication.

Contacts

for the LDC

Public Relations LDC
T. +49 231 9742 7000
E. pr@lead-discovery.de

Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund

Germany

 

for ISAS

ISAS e.V.
T: +49 (0)2 31.13 92-1082
E. presse@isas.de

Leibniz Institute for Analytical Sciences (ISAS)
Bunsen-Kirchhoff-Straße 11
44139 Dortmund

Germany

###

About the LDC

The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need.

The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the LDC is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential.

The LDC sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Apeiron, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Grünenthal, Johnson & Johnson Innovation, Merck KGaA, Qurient and Sotio as well as various investors and leading translational drug discovery centres around the globe.

Further information: www.lead-discovery.de

About ISAS

ISAS (Leibniz-Institut für Analytische Wissenschaften – ISAS – e.V.) develops fast, accurate, and cost-effective analytical procedures for health research in order to improve capabilities for the prevention, early diagnosis, and treatment of diseases. By combining expertise in chemistry, biology, physics, and computer science, we make measurable what cannot be measured yet. The institute was founded in Dortmund more than 60 years ago and has about 200 employees at two sites in Dortmund and one in Berlin Adlershof. Excellent interdisciplinary research, scientific qualification, and the transfer of our research findings to science, economy, and society are our key objectives to implement our mission.

Further information: www.isas.de

Tuesday July 11th, 2017
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Download PDF

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration

Daiichi Sankyo, Max Planck Innovation and LDC have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at LDC.

continue

Tokyo, Japan, Basking Ridge, NJ and Dortmund, Germany – (July 11, 2017) – Daiichi Sankyo Co., Limited (hereafter, Daiichi Sankyo), Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center.

This new partnership builds on biology insights in the field of transcriptional regulation from the work of Prof. Matthias Geyer at the Max Planck Institute of Molecular Physiology in Dortmund and the Research Center caesar (Center of Advanced European Studies and Research) in Bonn, Germany. Combined with the Lead Discovery Center’s strong drug discovery expertise in the design of highly selective kinase inhibitors, Daiichi Sankyo, Max Planck researchers and the Lead Discovery Center will now closely cooperate to further optimize these novel compounds that target cancer cell transcription and proliferation.

Daiichi Sankyo together with the Max Planck Society, supported by Max Planck Foundation, will jointly fund the respective drug discovery efforts at the Lead Discovery Center. Once the project has achieved proof-of-concept in relevant in vivo models, Daiichi Sankyo has the exclusive rights to license the program at pre-defined terms for subsequent preclinical and clinical development. The agreement includes an upfront payment as well as development and sales milestones plus royalties. The licensing revenues will be shared between Max Planck Society, the Lead Discovery Center and all contributing researchers and institutions

“The Lead Discovery Center is our prime partner for innovative drug discovery projects and developing novel compounds with a high therapeutic potential from the Max Planck Institutes. This agreement with Daiichi Sankyo, a recognized leader in the development and supply of innovative pharmaceutical products, again shows the high quality of research projects driven at the Max Planck laboratories. Moreover, the agreement is a great opportunity to advance the research findings into pharmaceutical development, providing potential new treatment options for patients with cancer,” according to Dr. Matthias Stein-Gerlach, patent and licensing manager at Max Planck Innovation, Max Planck Society´s technology transfer organization.

“This project collaboration and option agreement is building on the excellent experiences that Daiichi Sankyo and the Lead Discovery Center previously made from a discovery alliance that started in 2014, as well as close ties and many interactions between Daiichi Sankyo and the Max Planck Society, such as the collaboration with the Axel Ullrich lab. Max Planck Innovation has been instrumental to close this partnership,” adds Dr. Bert Klebl, Managing Director and CSO at the Lead Discovery Center.

“It is a great pleasure for us to start this research collaboration with Max Planck Innovation and the Lead Discovery Center to further generate innovation for our cancer drug discovery efforts,” said Antoine Yver, MD, MSc, Executive Vice President and Global Head of Oncology Research and Development, Daiichi Sankyo. “We are excited about the integration of Max Planck Society’s high quality science and the Lead Discovery Center’s expertise in lead discovery into Daiichi Sankyo’s drug research and development platform.”
Daiichi Sankyo, the Lead Discovery Center and the Max Planck Society aim to further expand their collaboration into additional programs in the future.

About Max Planck Innovation
Max Planck Innovation is responsible for the technology transfer of the Max Planck Society and, as such, serves as a link between industry and basic research. With its interdisciplinary team it advises and supports scientists in evaluating their inventions, filing patents, and founding companies. Max Planck Innovation offers the industry unique access to the innovations of the Max Planck Institutes, and therefore performs an important task: the transfer of basic research results into products, which contributes to economic and social progress.

For more information, please visit: www.max-planck-innovation.de

About Daiichi Sankyo Cancer Enterprise
The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our Antibody Drug Conjugate (ADC) and Acute Myeloid Leukemia (AML) Franchises, our cancer pipeline includes more than 20 small molecules, monoclonal antibodies and ADCs stemming from our powerful research engines: our two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA.

For more information, please visit: www.DSCancerEnterprise.com

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.  Daiichi Sankyo, Inc. headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group.

 

For more information, please visit: www.dsi.com

Tuesday April 11th, 2017
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
Download PDF

LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.

continue

Dortmund, Germany and Prague, Czech Republic, April 11, 2017 – The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.
Under the terms of the agreement, the LDC and its academic partners will perform further lead optimization and identify corresponding biomarkers for the program in collaboration with SOTIO. Upon nomination of a pre-clinical candidate, SOTIO will be responsible for the preclinical and clinical development as well as subsequent marketing and commercialization.
The LDC is eligible to receive research funding from SOTIO as well as upfront, development and sales milestone payments plus royalties on net sales of the product. Any revenues received by the LDC will be shared with the academic inventors, the Max Planck Institute for Biology of Ageing and the Max Planck Society. Financial details were not disclosed.
“We are excited to collaborate with SOTIO”, said Dr Bert Klebl, CEO of the LDC. “The team at SOTIO combines strong, global development expertise with the dynamic spirit of a mid-sized innovation leader. This makes them an ideal partner for translating the results of our collaborative efforts with the Max Planck team into novel therapies. Together we have investigated and developed a completely new molecular mechanism for the potential future therapy of cancer patients. With SOTIO on board, we are perfectly positioned to progress this new drug candidate to patients as fast as possible.”

Ladislav Bartonicek, CEO of SOTIO said, “Targeting cancer metabolism is a highly attractive and innovative approach for the treatment of cancer. Based on the world-class research at Max Planck, the team at LDC has generated very interesting lead candidates on this first-in-class cancer metabolism program with a promising safety and efficacy profile. We very much look forward to our collaboration with Max Planck and the LDC.”

About SOTIO

SOTIO is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is its proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products. SOTIO is also collaborating with NBE Therapeutics on the development of novel antibody-drug conjugate products (ADC) and with Cytune Pharma on developing novel IL15-based immunotherapies for the treatment of cancer. SOTIO has facilities in Europe, the United States, China and Russia.

Further information at: www.sotio.com

Contact

Richard Kapsa
Head of Communications
T. +420 603 280 971
E. kapsa@sotio.com
SOTIO a.s.
Jankovcova 1518/2
170 00 Prague
Czech Republic

Monday March 20th, 2017
Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases First project from LDC's agreement with Arix
Download PDF
Click here

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases First project from LDC's agreement with Arix

Arix Bioscience plc (LSE:ARIX), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center, Max Planck Innovation, and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.

continue

First project from Arix’s agreement with LDC

LONDON, 20 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI), and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.

Under the terms of the agreement, Arix Bioscience will fund and manage experimental work that builds on fundamental discoveries from the faculty of cardiovascular medicine and diabetes at the University of Leeds and LDC, focusing on the development of antagonists of a novel target for a variety of metabolic indications.

LDC, established by Max Planck Innovation and the Max Planck Society to capitalise on the potential of research from Max Planck Institutes, takes basic pathobiology or novel targets from academia and uses its integrated drug discovery platform to produce new candidate therapies for development.

This collaboration originated from a strategic agreement signed between Arix Bioscience and LDC in 2016, under which the LDC shares pipeline projects with Arix Bioscience. This is the first project to arise from this agreement.

Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: “Arix Bioscience aims to identify the best innovation in healthcare and life science and to use our permanent capital approach and strategic insight to support scientific teams in converting this innovation into proprietary development projects.

“We recently raised £100m in an initial public offering on the London Stock Exchange from a range of high quality investors who are supportive of our strategy and enthusiastic about our pipeline. We believe the combination of capital and strategic guidance we can offer can have a transformative impact on early-stage scientific discovery.”

“This collaboration with LDC and the University of Leeds on metabolic projects is the first fruit of Arix’s partnership with the Lead Discovery Center and Max Planck Innovation GmbH, which demonstrates our ability to convert our high-quality relationships into tangible projects based on academic scientific excellence with long-term commercial potential.”

For more information, please contact:

Arix Bioscience PLC
Joe Anderson, CEO
+44 (0) 20 7290 1052

Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com

About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com

About the University of Leeds
The University of Leeds has a long-standing history of working with entrepreneurs and venture firms to take innovative technologies discovered within its academic faculties through into commercialisation. The University has a strong track record in commercialisation with over 100 spin-out companies created since 1995 – the second highest number of any UK university – including 34 currently active and seven of which are market listed.